Get the Stockscreener App
0.3784
4.32%
-0.0116
Hcw Biologics Inc stock is traded at $0.3784, with a volume of 103.74K.
It is down -4.32% in the last 24 hours and down -32.11% over the past month.
HCW Biologics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen the health span by disrupting the link between chronic, low-grade inflammation and age-related diseases. The company has developed TOBI discovery platform, or Tissue factor-based fusion discovery platform, for the design of category-defining immunotherapeutic drugs. It has selected two molecules as its product candidate; HCW9218 and HCW9302. HCW9218 is a bifunctional immunotherapeutic designed with the capabilities to neutralize transforming growth and stimulate immune cells. HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes.
See More
Previous Close:
$0.39
Open:
$0.376
24h Volume:
103.74K
Relative Volume:
0.01
Market Cap:
$1.33M
Revenue:
$422.00K
Net Income/Loss:
$-22.21M
P/E Ratio:
-0.0271
EPS:
-13.9584
Net Cash Flow:
$-12.98M
1W Performance:
-50.41%
1M Performance:
-32.11%
6M Performance:
-90.88%
1Y Performance:
-96.91%
1-Day Range:
$0.3627
$0.3795
1-Week Range:
$0.3619
$0.7888
52-Week Range:
$0.3619
$17.80
Hcw Biologics Inc Stock (HCWB) Company Profile
Name
Hcw Biologics Inc
Sector
Industry
Phone
954-842-2024
Address
2929 N COMMERCE PKWY, MIRAMAR
Compare HCWB vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HCWB
Hcw Biologics Inc
|
0.3784 | 1.37M | 422.00K | -22.21M | -12.98M | -13.96 |
VRTX
Vertex Pharmaceuticals Inc
|
451.39 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
754.55 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
329.82 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
687.64 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
147.26 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Hcw Biologics Inc Stock (HCWB) Latest News
HCW Biologics (HCWB) Projected to Post Earnings on Wednesday - Defense World
HCW Biologics highlights positive findings for CAR-T therapy manufacturing - MSN
If You Invested $1,000 in Hcw Biologics Inc. (HCWB) - Stock Titan
HCWB Technical Analysis & Stock Price Forecast - Intellectia AI
HCWB stock soars pre-market on positive research results for CAR-T cell therapy - MSN
HCW Biologics receives $7M upfront fee from China licensee By Investing.com - Investing.com South Africa
HCW Biologics Grants Exclusive Worldwide License for HCW11-006 to Trimmune with $7M Upfront Payment and Future Royalties 1 - Minichart
HCW Biologics Secures $7M License Deal for HCW11-006 - TipRanks
HCW Biologics Closes Exclusive Global License for HCW11-006, Receives Upfront Payment - TradingView
HCW Biologics receives $7M upfront fee from China licensee - Investing.com
[8-K] HCW Biologics Inc. Reports Material Event - Stock Titan
HCW Biologics Inc. Receives $7 Million Upfront License Fee from Beijing Trimmune Biotech for HCW11-006 Development and Commercialization Rights - Quiver Quantitative
Hcw Biologics Closes Exclusive Worldwide License For Hcw11-006 – A High Potential Fusion Immunotherapeutic - TradingView
New fusion immunotherapy deal brings HCW Biologics $7M upfront - Stock Titan
HCWB HCW Biologics (NASDAQ) +81% pre market 17 Mar 2026: CAR-T paper lifts volume - Meyka
HCW Biologics Announces Positive Research Results for CAR-T Cell Therapy Manufactured Utilizing Its Commercial-Ready Proprietary Compound, HCW9206, Published in Science Advances - Investing News Network
Small Cap Stocks To Keep An Eye OnMarch 16th - MarketBeat
HCW Biologics Inc. (HCWB) Stock: Science Advances Study Highlights Next-Gen CAR-T Manufacturing Strategy - parameter.io
HCW Biologics’ compound shows promise in CAR-T cell production By Investing.com - Investing.com Canada
Promising Pharmaceutical Stocks To Keep An Eye OnMarch 16th - MarketBeat
Trading Volume Surges in Biotech, Tech, and Energy Stocks | Market RecapNews and Statistics - IndexBox
HCW Biologics (HCWB) spikes 71% as micro-cap volatility returns after Nasdaq compliance and recent financing - Quiver Quantitative
HCW Biologics announces positive research results for CAR-T cell therapy - TipRanks
HCWB Stock Soars Pre-Market On Positive Research Results For CAR-T Cell Therapy - Asianet Newsable
HCW Biologics’ compound shows promise in CAR-T cell production - Investing.com
HCW Biologics reports positive CAR-T cell therapy research results By Investing.com - Investing.com Australia
HCW Biologics Announces Positive Research Results for CAR-T - GlobeNewswire
HCW Biologics (NASDAQ: HCWB) seeks approval for large warrant issuances and deep repricing - Stock Titan
HCW Biologics restructures obligations to regain Nasdaq compliance - MSN
Hedge Fund Moves: What is HCW Biologics Incs revenue forecastLayoff News & Low Risk Entry Point Tips - baoquankhu1.vn
AI Stocks: Will HCW Biologics Inc outperform tech stocksTrade Volume Report & Expert Curated Trade Ideas - baoquankhu1.vn
Buyout Rumor: Can HCW Biologics Inc stock double in the next yearWeekly Investment Report & Free Weekly Chart Analysis and Trade Guides - baoquankhu1.vn
AI Stocks: Is HCW Biologics Inc forming a breakout patternWeekly Gains Summary & Reliable Price Breakout Alerts - baoquankhu1.vn
HCWB Earnings History & Surprises | EPS & Revenue Results | HCW BIOLOGICS INC (NASDAQ:HCWB) - ChartMill
HCW Biologics (NASDAQ: HCWB) seeks warrant approvals at Apr 27 meeting - Stock Titan
HCWB Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
HCW Biologics Regains Nasdaq Listing Compliance, Faces Ongoing Oversight - The Globe and Mail
HCW Biologics regains compliance with all continued listing rules for Nasdaq per Nasdaq determination letter - marketscreener.com
HCW Biologics Regains Compliance with All Continued Listing Rules for Nasdaq Per Nasdaq Determination Letter - The Manila Times
HCW Biologics (NASDAQ: HCWB) back in full Nasdaq compliance - Stock Titan
HCW Biologics : February 2026 - marketscreener.com
EV Market: Is HCW Biologics Inc gaining market shareJuly 2025 Sector Moves & Stock Timing and Entry Methods - baoquankhu1.vn
EDGAR Filing Documents for 0000950170-24-127198 - SEC.gov
HCW Biologics Completes Follow-On Offering to Fund Pipeline - The Globe and Mail
HCW Biologics Prices $1.5 Million Follow-On Offering of 2.48M Units at $0.6055 - TradingView
HCW Biologics Prices $1.5 Million Unit Offering - marketscreener.com
HCW Biologics lines up $1.5M, cuts warrant price to $0.6055 - Stock Titan
HCW Biologics Announces Pricing of $1.5 Million Follow-On Offering Priced At-The-Market Under NASDAQ Rules - The Manila Times
HCW Biologics Announces Follow-On Offering Pricing - Intellectia AI
HCW Biologics Inc. Announces Pricing of Follow-On Offering to Fund Immunotherapy Development - Quiver Quantitative
HCW Biologics Announces Pricing of $1.5 Million Follow-On Offering Priced At-The-Market Under NASDAQ Rules - GlobeNewswire Inc.
Hcw Biologics Inc Stock (HCWB) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.99%
3.03%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):